,,ii ,calendar ,no4 #dbg #aadth ,,congress #b;d ,session ,s4 #bgjj ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,march #ag1 #bjaf,mr4 ,alexander 7for himself and ,mrs4 ,murray7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,april #ah1 #bjaf,reported by ,mr4 ,alexander1 with an amendment,strike out all after the enacting clause and insert the part printed in italic ,a ,,bill ,to update the authorizing provisions relating to the workforces of the ,national ,institutes of ,health and the ,food and ,drug ,administration1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,,fda and ,,nih ,workforce ,authorities ,modernization ,act4 #b4 ,silvio ,o4 ,conte senior biomedical research service 7a7 ,hiring and retention authority ,section #bbh of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bcg7 is amended-- 7#a7 in the section heading1 by inserting and ,biomedical ,product ,assessment after ,research2 7#b7 in subsection 7a7-- 7,a7 in paragraph 7#a71 by striking ,silvio ,o4 ,conte ,senior ,biomedical ,research ,service1 not to exceed #ejj members and inserting ,silvio ,o4 ,conte ,senior ,biomedical ,research and ,biomedical ,product ,assessment ,service 7in this section referred to as the ,service71 not to exceed #b1jjj members1 the purpose of which is to recruit and retain outstanding and qualified scientific and technical experts in the fields of biomedical research1 clinical research evaluation1 and biomedical product assessment2 7,b7 by amending paragraph 7#b7 to read as follows3 7#b7 ,the authority established in paragraph 7#a7 may not be construed to require the ,secretary to reduce the number of employees serving under any other employment system in order to offset the number of members serving in the ,service4 2 and 7,c7 by adding at the end the following3 7#c7 ,the ,secretary shall assign experts under this section to agencies within the ,department of ,health and ,human ,services taking into account the need for the expertise of such expert4 2 7#c7 in subsection 7b7-- 7,a7 in the matter preceding paragraph 7#a71 by striking or clinical research evaluation and inserting 1 clinical research evaluation1 or biomedical product assessment2 and 7,b7 in paragraph 7#a71 by inserting or a doctoral or master's level degree in engineering1 bioinformatics1 or a related or emerging field1 after the comma2 7#d7 in subsection 7d77#b71 by striking and shall not exceed the rate payable for level ,i of the ,executive ,schedule unless approved by the ,president under section #ecgg7;d77#b7 of title #e1 ,united ,states ,code and inserting and shall not exceed the amount of annual compensation 7excluding expenses7 specified in section #ajb of title #c1 ,united ,states ,code2 7#e7 by striking subsection 7e72 and 7#f7 by redesignating subsections 7f7 and 7g7 as subsections 7e7 and 7f71 respectively4 7b7 ,,gao study 7#a7 ,in general ,the ,comptroller ,general of the ,united ,states shall conduct a study of the effectiveness of the amendments to section #bbh of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bcg7 made by subsection 7a7 and the impact of such amendments1 if any1 on all agencies or departments of the ,department of ,health and ,human ,services1 and1 not later than #d years after the date of enactment of this ,act1 shall submit a report based on such study to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives4 7#b7 ,content of study and report ,the study and report under paragraph 7#a7 shall include an examination of the extent to which recruitment and retention of outstanding and qualified scientific1 medical1 or technical experts in the fields of biomedical research1 clinical research evaluation1 and biomedical product assessment has improved or otherwise has been affected by the amendments to section #bbh of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bcg7 made by subsection 7a71 including by determining1 during the period between the date of enactment of this ,act and the completion of the study-- 7,a7 the total number of members recruited and retained under the ,senior ,biomedical ,research and ,biomedical ,product ,assessment ,service under such section #bbh1 and the effect of increasing the number of members eligible for such ,service2 7,b7 the number of members of such ,senior ,biomedical ,research and ,biomedical ,product ,assessment ,service hired with a doctoral level degree in biomedicine or a related field1 or doctoral or master's level degree in engineering1 bioinformatics1 or a related or emerging field2 and 7,c7 how many ,senior ,biomedical ,research and ,biomedical ,product ,assessment ,service members have been hired by each agency or department of the ,department of ,health and ,human ,services1 and how such ,department assigns such members to each agency or department4 #c4 ,hiring authority for scientific1 technical1 and professional personnel 7a7 ,in general ,the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended by inserting after section #gad 7#ba ,u4,s4,c4 #cgi;d-#c7 the following3 #gad;,a4 ,hiring authority for scientific1 technical1 and professional personnel 7a7 ,in general ,the ,secretary may1 without regard to the provisions of title #e1 ,united ,states ,code1 governing appointments in the competitive service1 appoint outstanding and qualified candidates to scientific1 technical1 or professional positions that support the development1 review1 and regulation of medical products4 ,such positions shall be within the competitive service4 7b7 ,compensation 7#a7 ,in general ,notwithstanding any other provision of law1 including any requirement with respect to ,general ,schedule pay rates under subchapter ,,iii of chapter #ec of title #e1 ,united ,states ,code1 and consistent with the requirements of paragraph 7#b71 the ,commissioner of ,food and ,drugs may determine and fix-- 7,a7 the annual rate of pay of any individual appointed under subsection 7a72 and 7,b7 for purposes of retaining qualified employees1 the annual rate of pay for any qualified scientific1 technical1 or professional personnel appointed to a position described in subsection 7a7 before the date of enactment of this section4 7#b7 ,limitation ,the annual rate of pay established pursuant to paragraph 7#a7 may not exceed the amount of annual compensation 7excluding expenses7 specified in section #ajb of title #c1 ,united ,states ,code4 7#c7 ,public availability ,the annual rate of pay provided to an individual in accordance with this section shall be publicly available information4 7c7 ,rule of construction ,the authorities under this section shall not be construed to affect the authority provided under section #gad4 7d7 ,report on workforce planning 7#a7 ,in general ,not later than #ah months after the date of enactment of the ,,fda and ,,nih ,workforce ,authorities ,modernization ,act1 the ,secretary shall submit a report on workforce planning to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives that examines the extent to which the ,food and ,drug ,administration has a critical need for qualified individuals for scientific1 technical1 or professional positions1 including-- 7,a7 an analysis of the workforce needs at the ,food and ,drug ,administration and the ,secretary's strategic plan for addressing such needs1 including through use of the authority under this section2 and 7,b7 a recruitment and retention plan for hiring qualified scientific1 technical1 and professional candidates1 which may include the use of-- 7i7 recruitment through non-governmental recruitment or placement agencies2 7ii7 recruitment through academic institutions2 7iii7 recruitment or hiring bonuses1 if applicable2 7iv7 recruitment using targeted direct hiring authorities2 and 7v7 retention of qualified scientific1 technical1 and professional employees using the authority under this section1 or other applicable authorities of the ,secretary4 7#b7 ,recommendations ,the report under paragraph 7#a7 may include the recommendations of the ,commissioner of ,food and ,drugs that would help the ,food and ,drug ,administration to better recruit and retain qualified individuals for scientific1 technical1 or professional positions at the agency4 4 7b7 ,,gao study and report 7#a7 ,in general ,the ,comptroller ,general of the ,united ,states shall conduct a study of the ability of the ,food and ,drug ,administration to hire1 train1 and retain qualified scientific1 technical1 and professional staff1 not including contractors1 necessary to fulfill the mission of the ,food and ,drug ,administration to protect and promote public health4 ,not later than ,january #a1 #bjbb1 the ,comptroller ,general shall submit a report on such study to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives4 7#b7 ,contents of study ,the ,comptroller ,general shall include in the study and report under paragraph 7#a7-- 7,a7 information about the progress of the ,food and ,drug ,administration in recruiting and retaining qualified scientific1 technical1 and professional staff outstanding in the field of biomedical research1 clinical research evaluation1 and biomedical product assessment2 7,b7 the extent to which critical staffing needs exist at the ,food and ,drug ,administration1 and barriers to hiring1 training1 and retaining qualified staff1 if any2 7,c7 an examination of the recruitment and retention strategies of the ,food and ,drug ,administration1 including examining any strategic workforce plan1 focused on improving scientific1 technical1 and professional staff recruitment and retention2 and 7,d7 recommendations for potential improvements that would address staffing needs of the ,food and ,drug ,administration4 #d4 ,establishment of food and drug administration intercenter institutes 7a7 ,in general ,chapter ,x of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cia et seq47 is amended by adding at the end the following3 #ajad4 ,food and ,drug ,administration ,intercenter ,institutes 7a7 ,in general ,the ,secretary shall establish one or more ,intercenter ,institutes within the ,food and ,drug ,administration 7referred to in this section as an ,institute7 for a major disease area or areas4 ,with respect to the major disease area of focus of an ,institute1 such ,institute shall develop and implement processes for coordination of activities1 as applicable to such major disease area or areas1 between the ,center for ,drug ,evaluation and ,research1 the ,center for ,biologics ,evaluation and ,research1 and the ,center for ,devices and ,radiological ,health 7for the purposes of this section1 referred to as the ,centers74 ,such activities may include-- 7#a7 coordination of staff from the ,centers with diverse product expertise in the diagnosis1 cure1 mitigation1 treatment1 or prevention of the specific diseases relevant to the major disease area of focus of the ,institute2 7#b7 streamlining1 where appropriate1 the review of medical products to diagnose1 cure1 mitigate1 treat1 or prevent the major disease area of focus of the ,institute1 applying relevant standards under sections #eje1 #eaj7k71 and #eae of this ,act and section #cea of the ,public ,health ,service ,act1 and other applicable authorities2 7#c7 promotion of scientific programs within the ,centers related to the major disease area of focus of the ,institute2 7#d7 development of programs and enhancement of strategies to recruit1 train1 and provide continuing education opportunities for the personnel of the ,centers with expertise related to the major disease area of focus of the ,institute2 7#e7 enhancement of the interactions of the ,centers with patients1 sponsors1 and the external biomedical community regarding the major disease area of focus of the ,institute2 and 7#f7 facilitation of the collaborative relationships of the ,centers with other agencies within the ,department of ,health and ,human ,services regarding the major disease area of focus of the ,institute4 7b7 ,implementation plan ,prior to establishing an ,institute under subsection 7a71 and not later than #a year after the date of enactment of the ,,fda and ,,nih ,workforce ,authorities ,modernization ,act1 the ,secretary shall publish a draft implementation plan for such ,institute1 and provide for not less than #fj calendar days for public comment on such plan4 7c7 ,timing ,the ,secretary shall establish at least one ,institute under subsection 7a7 within #a year of the closing of the public comment period under subsection 7b71 unless the ,secretary determines that establishing such ,institute would not be feasible or would not benefit the public health1 and publishes such determination on the public ,internet website of the ,food and ,drug ,administration4 7d7 ,termination of institutes ,the ,secretary may terminate any ,institute established pursuant to this section if the ,secretary determines such ,institute is no longer benefitting the public health4 ,not less than #fj days prior to so terminating an ,institute1 the ,secretary shall provide public notice1 including the rationale for such termination4 4 7b7 ,technical amendments ,chapter ,x of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cia et seq47 is amended-- 7#a7 by redesignating section #ajab as section #ajac2 and 7#b7 by redesignating the second section #ajaa 7with respect to improving the training of ,state1 local1 territorial1 and tribal food safety officials71 as added by section #bji7;a7 of the ,,fda ,food ,safety ,modernization ,act 7,public ,law #aaa-cec71 as section #ajab4 #e4 ,scientific meetings 7a7 ,in general ,scientific meetings that are attended by scientific or medical personnel1 or other professionals1 of the ,department of ,health and ,human ,services for whom attendance at such meeting is directly related to their professional duties and the mission of the ,department-- 7#a7 shall not be considered conferences for the purposes of complying with ,federal reporting requirements contained in annual appropriations ,acts or in this section2 and 7#b7 shall not be considered conferences for purposes of a restriction contained in an annual appropriations ,act1 based on ,office of ,management and ,budget ,memorandum ,m-#ab-ab or any other regulation restricting such travel4 7b7 ,limitation ,nothing in this section shall be construed to exempt travel for scientific meetings from ,federal regulations relating to travel4 7c7 ,reports ,each operating division of the ,department of ,health and ,human ,services shall prepare1 and post on an ,internet website of the operating division1 an annual report on scientific meeting attendance and related travel spending for each fiscal year4 ,such report shall include-- 7#a7 general information concerning the scientific meeting activities involved2 7#b7 information concerning the total amount expended for such meetings2 7#c7 a description of all such meetings that were attended by scientific or medical personnel1 or other professionals1 of each such operating division where the total amount expended by the operating division associated with each such meeting are in excess of #cj1jjj1 including-- 7,a7 the total amount of meeting expenses incurred by the operating division for such meeting2 7,b7 the location of such meeting2 7,c7 the date of such meeting2 7,d7 a brief explanation on how such meeting advanced the mission of the operating division2 and 7,e7 the total number of individuals whose travel expenses or other scientific meeting expenses were paid by the operating division2 and 7#d7 with respect to any such meeting where the total expenses to the operating division exceeded #aej1jjj1 a description of the exceptional circumstances that necessitated the expenditure of such amounts4 #f4 ,reagan-,udall ,foundation for the ,food and ,drug ,administration 7a7 ,board of ,directors 7#a7 ,composition and size ,section #ggj7;d77#a77;,c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;dd7d77#a77;,c77 is amended-- 7,a7 by redesignating clause 7ii7 as clause 7iii72 7,b7 by inserting after clause 7i7 the following3 7ii7 ,additional members ,the ,board1 through amendments to the bylaws of the ,foundation1 may provide that the number of voting members of the ,board shall be a number 7to be specified in such amendment7 greater than #ad4 ,any ,board positions that are established by any such amendment shall be appointed 7by majority vote7 by the individuals who1 as of the date of such amendment1 are voting members of the ,board and persons so appointed may represent any of the categories specified in subclauses 7,i7 through 7,v7 of clause 7i71 so long as no more than #cj percent of the total voting members of the ,board 7including members whose positions are established by such amendment7 are representatives of the general pharmaceutical1 device1 food1 cosmetic1 and biotechnology industries4 2 and 7,c7 in clause 7iii77,i71 as redesignated by subparagraph 7,a71 by striking ,the ex officio members shall ensure and inserting ,the ex officio members1 acting pursuant to clause 7i71 and the ,board1 acting pursuant to clause 7ii71 shall ensure4 7#b7 ,federal employees allowed to serve on ,board ,clause 7iii77,,ii7 of section #ggj7;d77#a77;,c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;dd7d77#a77;,c771 as redesignated by paragraph 7#a77;,a71 is amended by adding at the end the following3 ,for purposes of this section1 the term employee of the ,federal ,government does not include a special ,government employee1 as that term is defined in section #bjb7;a7 of title #ah1 ,united ,states ,code44 7#c7 ,staggered terms ,subparagraph 7,a7 of section #ggj7;d77#c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;dd7d77#c77 is amended to read as follows3 7,a7 ,term ,the term of office of each member of the ,board appointed under paragraph 7#a77;,c77i71 and the term of office of any member of the ,board whose position is established pursuant to paragraph 7#a77;,c77ii71 shall be #d years1 except that-- 7i7 the terms of offices for the members of the ,board initially appointed under paragraph 7#a77;,c77i7 shall expire on a staggered basis as determined by the ex officio members2 and 7ii7 the terms of office for the persons initially appointed to positions established pursuant to paragraph 7#a77;,c77ii7 may be made to expire on a staggered basis1 as determined by the individuals who1 as of the date of the amendment establishing such positions1 are members of the ,board4 4 7b7 ,executive ,director compensation ,section #ggj7;g77#b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;dd7g77#b77 is amended by striking but shall not be greater than the compensation of the ,commissioner4 7c7 ,separation of ,funds ,section #ggj7m7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;dd7m77 is amended by striking are held in separate accounts from funds received from entities under subsection 7i7 and inserting are managed as individual programmatic funds under subsection 7i71 according to best accounting practices4 #g4 ,,nih research information collection exempted from ,paperwork ,reduction ,act ,section #cja of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bda7 is amended by adding to the end the following3 7f7 ,paperwork reduction ,subchapter ,i of chapter #ce of title #dd1 ,united ,states ,code1 shall not apply to the collection of information during the conduct of research by the ,national ,institutes of ,health4 4 #h4 ,studies ,the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended-- 7#a7 in section #eje7k77#e7 7#ba ,u4,s4,c4 #cee7k77#e77-- 7,a7 in subparagraph 7,a71 by inserting and after the semicolon2 7,b7 by striking subparagraph 7,b72 and 7,c7 by redesignating subparagraph 7,c7 as subparagraph 7,b72 7#b7 in section #eje;,a 7#ba ,u4,s4,c4 #cee;a71 by striking subsection 7p72 7#c7 in section #eje;,b 7#ba ,u4,s4,c4 #cee;c7-- 7,a7 by striking subsection 7l72 and 7,b7 by redesignating subsection 7m7 as subsection 7l72 and 7#d7 in section #ebc 7#ba ,u4,s4,c4 #cfjm71 by striking subsection 7d74 #a4 ,short title ,this ,act may be cited as the ,,fda and ,,nih ,workforce ,authorities ,modernization ,act4 #b4 ,silvio ,o4 ,conte senior biomedical research service 7a7 ,hiring and retention authority ,section #bbh of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bcg7 is amended-- 7#a7 in the section heading1 by inserting and ,biomedical ,product ,assessment after ,research2 7#b7 in subsection 7a7-- 7,a7 in paragraph 7#a71 by striking ,silvio ,o4 ,conte ,senior ,biomedical ,research ,service1 not to exceed #ejj members and inserting ,silvio ,o4 ,conte ,senior ,biomedical ,research and ,biomedical ,product ,assessment ,service 7in this section referred to as the ,service71 not to exceed #b1jjj members1 the purpose of which is to recruit and retain outstanding and qualified scientific and technical experts in the fields of biomedical research1 clinical research evaluation1 and biomedical product assessment2 7,b7 by amending paragraph 7#b7 to read as follows3 7#b7 ,the authority established in paragraph 7#a7 may not be construed to require the ,secretary to reduce the number of employees serving under any other employment system in order to offset the number of members serving in the ,service4 2 and 7,c7 by adding at the end the following3 7#c7 ,the ,secretary shall assign experts under this section to agencies within the ,department of ,health and ,human ,services taking into account the need for the expertise of such expert4 2 7#c7 in subsection 7b7-- 7,a7 in the matter preceding paragraph 7#a71 by striking or clinical research evaluation and inserting 1 clinical research evaluation1 or biomedical product assessment2 and 7,b7 in paragraph 7#a71 by inserting or a doctoral or master's level degree in engineering1 bioinformatics1 or a related or emerging field1 after the comma2 7#d7 in subsection 7d77#b71 by striking and shall not exceed the rate payable for level ,i of the ,executive ,schedule unless approved by the ,president under section #ecgg7;d77#b7 of title #e1 ,united ,states ,code and inserting and shall not exceed the amount of annual compensation 7excluding expenses7 specified in section #ajb of title #c1 ,united ,states ,code2 7#e7 by striking subsection 7e72 and 7#f7 by redesignating subsections 7f7 and 7g7 as subsections 7e7 and 7f71 respectively4 7b7 ,,gao study 7#a7 ,in general ,the ,comptroller ,general of the ,united ,states shall conduct a study of the effectiveness of the amendments to section #bbh of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bcg7 made by subsection 7a7 and the impact of such amendments1 if any1 on all agencies or departments of the ,department of ,health and ,human ,services1 and1 not later than #d years after the date of enactment of this ,act1 shall submit a report based on such study to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives4 7#b7 ,content of study and report ,the study and report under paragraph 7#a7 shall include an examination of the extent to which recruitment and retention of outstanding and qualified scientific1 medical1 or technical experts in the fields of biomedical research1 clinical research evaluation1 and biomedical product assessment has improved or otherwise has been affected by the amendments to section #bbh of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bcg7 made by subsection 7a71 including by determining1 during the period between the date of enactment of this ,act and the completion of the study-- 7,a7 the total number of members recruited and retained under the ,senior ,biomedical ,research and ,biomedical ,product ,assessment ,service under such section #bbh1 and the effect of increasing the number of members eligible for such ,service2 7,b7 the number of members of such ,senior ,biomedical ,research and ,biomedical ,product ,assessment ,service hired with a doctoral level degree in biomedicine or a related field1 or doctoral or master's level degree in engineering1 bioinformatics1 or a related or emerging field2 and 7,c7 how many ,senior ,biomedical ,research and ,biomedical ,product ,assessment ,service members have been hired by each agency or department of the ,department of ,health and ,human ,services1 and how such ,department assigns such members to each agency or department4 #c4 ,hiring authority for scientific1 technical1 and professional personnel 7a7 ,in general ,the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended by inserting after section #gad 7#ba ,u4,s4,c4 #cgi;d-#c7 the following3 #gad;,a4 ,hiring authority for scientific1 technical1 and professional personnel 7a7 ,in general ,the ,secretary may1 without regard to the provisions of title #e1 ,united ,states ,code1 governing appointments in the competitive service1 appoint outstanding and qualified candidates to scientific1 technical1 or professional positions that support the development1 review1 and regulation of medical products4 ,such positions shall be within the competitive service4 7b7 ,compensation 7#a7 ,in general ,notwithstanding any other provision of law1 including any requirement with respect to ,general ,schedule pay rates under subchapter ,,iii of chapter #ec of title #e1 ,united ,states ,code1 and consistent with the requirements of paragraph 7#b71 the ,commissioner of ,food and ,drugs may determine and fix-- 7,a7 the annual rate of pay of any individual appointed under subsection 7a72 and 7,b7 for purposes of retaining qualified employees1 the annual rate of pay for any qualified scientific1 technical1 or professional personnel appointed to a position described in subsection 7a7 before the date of enactment of this section4 7#b7 ,limitation ,the annual rate of pay established pursuant to paragraph 7#a7 may not exceed the amount of annual compensation 7excluding expenses7 specified in section #ajb of title #c1 ,united ,states ,code4 7#c7 ,public availability ,the annual rate of pay provided to an individual in accordance with this section shall be publicly available information4 7c7 ,rule of construction ,the authorities under this section shall not be construed to affect the authority provided under section #gad4 7d7 ,report on workforce planning 7#a7 ,in general ,not later than #ah months after the date of enactment of the ,,fda and ,,nih ,workforce ,authorities ,modernization ,act 1 the ,secretary shall submit a report on workforce planning to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives that examines the extent to which the ,food and ,drug ,administration has a critical need for qualified individuals for scientific1 technical1 or professional positions1 including-- 7,a7 an analysis of the workforce needs at the ,food and ,drug ,administration and the ,secretary's strategic plan for addressing such needs1 including through use of the authority under this section2 and 7,b7 a recruitment and retention plan for hiring qualified scientific1 technical1 and professional candidates1 which may include the use of-- 7i7 recruitment through non-governmental recruitment or placement agencies2 7ii7 recruitment through academic institutions2 7iii7 recruitment or hiring bonuses1 if applicable2 7iv7 recruitment using targeted direct hiring authorities2 and 7v7 retention of qualified scientific1 technical1 and professional employees using the authority under this section1 or other applicable authorities of the ,secretary4 7#b7 ,recommendations ,the report under paragraph 7#a7 may include the recommendations of the ,commissioner of ,food and ,drugs that would help the ,food and ,drug ,administration to better recruit and retain qualified individuals for scientific1 technical1 or professional positions at the agency4 4 7b7 ,,gao study and report 7#a7 ,in general ,the ,comptroller ,general of the ,united ,states shall conduct a study of the ability of the ,food and ,drug ,administration to hire1 train1 and retain qualified scientific1 technical1 and professional staff1 not including contractors1 necessary to fulfill the mission of the ,food and ,drug ,administration to protect and promote public health4 ,not later than ,january #a1 #bjbb1 the ,comptroller ,general shall submit a report on such study to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives4 7#b7 ,contents of study ,the ,comptroller ,general shall include in the study and report under paragraph 7#a7-- 7,a7 information about the progress of the ,food and ,drug ,administration in recruiting and retaining qualified scientific1 technical1 and professional staff outstanding in the field of biomedical research1 clinical research evaluation1 and biomedical product assessment2 7,b7 the extent to which critical staffing needs exist at the ,food and ,drug ,administration1 and barriers to hiring1 training1 and retaining qualified staff1 if any2 7,c7 an examination of the recruitment and retention strategies of the ,food and ,drug ,administration1 including examining any strategic workforce plan1 focused on improving scientific1 technical1 and professional staff recruitment and retention2 and 7,d7 recommendations for potential improvements that would address staffing needs of the ,food and ,drug ,administration4 #d4 ,establishment of ,food and ,drug ,administration ,intercenter ,institutes 7a7 ,in general ,chapter ,x of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cia et seq47 is amended by adding at the end the following3 #ajad4 ,food and ,drug ,administration ,intercenter ,institutes 7a7 ,in general ,the ,secretary shall establish one or more ,intercenter ,institutes within the ,food and ,drug ,administration 7referred to in this section as an ,institute7 for a major disease area or areas4 ,with respect to the major disease area of focus of an ,institute1 such ,institute shall develop and implement processes for coordination of activities1 as applicable to such major disease area or areas1 between the ,center for ,drug ,evaluation and ,research1 the ,center for ,biologics ,evaluation and ,research1 and the ,center for ,devices and ,radiological ,health 7for the purposes of this section1 referred to as the ,centers74 ,such activities may include-- 7#a7 coordination of staff from the ,centers with diverse product expertise in the diagnosis1 cure1 mitigation1 treatment1 or prevention of the specific diseases relevant to the major disease area of focus of the ,institute2 7#b7 streamlining1 where appropriate1 the review of medical products to diagnose1 cure1 mitigate1 treat1 or prevent the major disease area of focus of the ,institute1 applying relevant standards under sections #eje1 #eaj7k71 #eac7;f77#b71 and #eae of this ,act and section #cea of the ,public ,health ,service ,act1 and other applicable authorities2 7#c7 promotion of scientific programs within the ,centers related to the major disease area of focus of the ,institute2 7#d7 development of programs and enhancement of strategies to recruit1 train1 and provide continuing education opportunities for the personnel of the ,centers with expertise related to the major disease area of focus of the ,institute2 7#e7 enhancement of the interactions of the ,centers with patients1 sponsors1 and the external biomedical community regarding the major disease area of focus of the ,institute2 and 7#f7 facilitation of the collaborative relationships of the ,centers with other agencies within the ,department of ,health and ,human ,services regarding the major disease area of focus of the ,institute4 7b7 ,public process ,the ,secretary shall provide a period for public comment during the time that each ,institute is being implemented4 7c7 ,timing ,the ,secretary shall establish at least one ,institute under subsection 7a7 before the date that is #a year after the date of enactment of the ,,fda and ,,nih ,workforce ,authorities ,modernization ,act4 7d7 ,termination of institutes ,the ,secretary may terminate any ,institute established pursuant to this section if the ,secretary determines such ,institute is no longer benefitting the public health4 ,not less than #fj days prior to so terminating an ,institute1 the ,secretary shall provide public notice1 including the rationale for such termination4 4 7b7 ,technical amendments ,chapter ,x of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cia et seq47 is amended-- 7#a7 by redesignating section #ajab as section #ajac2 and 7#b7 by redesignating the second section #ajaa 7with respect to improving the training of ,state1 local1 territorial1 and tribal food safety officials71 as added by section #bji7;a7 of the ,,fda ,food ,safety ,modernization ,act 7,public ,law #aaa-cec71 as section #ajab4 #e4 ,scientific meetings 7a7 ,in general ,scientific meetings that are attended by scientific or medical personnel1 or other professionals1 of the ,department of ,health and ,human ,services for whom attendance at such meeting is directly related to their professional duties and the mission of the ,department-- 7#a7 shall not be considered conferences for the purposes of complying with ,federal reporting requirements contained in annual appropriations ,acts or in this section2 and 7#b7 shall not be considered conferences for purposes of a restriction contained in an annual appropriations ,act1 based on ,office of ,management and ,budget ,memorandum ,m-#ab-ab or any other regulation restricting such travel4 7b7 ,limitation ,nothing in this section shall be construed to exempt travel for scientific meetings from ,federal regulations relating to travel4 7c7 ,reports ,each operating division of the ,department of ,health and ,human ,services shall prepare1 and post on an ,internet website of the operating division1 an annual report on scientific meeting attendance and related travel spending for each fiscal year4 ,such report shall include-- 7#a7 general information concerning the scientific meeting activities involved2 7#b7 information concerning the total amount expended for such meetings2 7#c7 a description of all such meetings that were attended by scientific or medical personnel1 or other professionals1 of each such operating division where the total amount expended by the operating division associated with each such meeting are in excess of #cj1jjj1 including-- 7,a7 the total amount of meeting expenses incurred by the operating division for such meeting2 7,b7 the location of such meeting2 7,c7 the date of such meeting2 7,d7 a brief explanation on how such meeting advanced the mission of the operating division2 and 7,e7 the total number of individuals whose travel expenses or other scientific meeting expenses were paid by the operating division2 and 7#d7 with respect to any such meeting where the total expenses to the operating division exceeded #aej1jjj1 a description of the exceptional circumstances that necessitated the expenditure of such amounts4 #f4 ,reagan-,udall ,foundation for the ,food and ,drug ,administration 7a7 ,board of ,directors 7#a7 ,composition and size ,section #ggj7;d77#a77;,c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;dd7d77#a77;,c77 is amended-- 7,a7 by redesignating clause 7ii7 as clause 7iii72 7,b7 by inserting after clause 7i7 the following3 7ii7 ,additional members ,the ,board1 through amendments to the bylaws of the ,foundation1 may provide that the number of voting members of the ,board shall be a number 7to be specified in such amendment7 greater than #ad4 ,any ,board positions that are established by any such amendment shall be appointed 7by majority vote7 by the individuals who1 as of the date of such amendment1 are voting members of the ,board and persons so appointed may represent any of the categories specified in subclauses 7,i7 through 7,v7 of clause 7i71 so long as no more than #cj percent of the total voting members of the ,board 7including members whose positions are established by such amendment7 are representatives of the general pharmaceutical1 device1 food1 cosmetic1 and biotechnology industries4 2 and 7,c7 in clause 7iii77,i71 as redesignated by subparagraph 7,a71 by striking ,the ex officio members shall ensure and inserting ,the ex officio members1 acting pursuant to clause 7i71 and the ,board1 acting pursuant to clause 7ii71 shall ensure4 7#b7 ,federal employees allowed to serve on ,board ,clause 7iii77,,ii7 of section #ggj7;d77#a77;,c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;dd7d77#a77;,c771 as redesignated by paragraph 7#a77;,a71 is amended by adding at the end the following3 ,for purposes of this section1 the term employee of the ,federal ,government does not include a special ,government employee1 as that term is defined in section #bjb7;a7 of title #ah1 ,united ,states ,code44 7#c7 ,staggered terms ,subparagraph 7,a7 of section #ggj7;d77#c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;dd7d77#c77 is amended to read as follows3 7,a7 ,term ,the term of office of each member of the ,board appointed under paragraph 7#a77;,c77i71 and the term of office of any member of the ,board whose position is established pursuant to paragraph 7#a77;,c77ii71 shall be #d years1 except that-- 7i7 the terms of offices for the members of the ,board initially appointed under paragraph 7#a77;,c77i7 shall expire on a staggered basis as determined by the ex officio members2 and 7ii7 the terms of office for the persons initially appointed to positions established pursuant to paragraph 7#a77;,c77ii7 may be made to expire on a staggered basis1 as determined by the individuals who1 as of the date of the amendment establishing such positions1 are members of the ,board4 4 7b7 ,executive ,director compensation ,section #ggj7;g77#b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;dd7g77#b77 is amended by striking but shall not be greater than the compensation of the ,commissioner4 7c7 ,separation of ,funds ,section #ggj7m7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;dd7m77 is amended by striking are held in separate accounts from funds received from entities under subsection 7i7 and inserting are managed as individual programmatic funds under subsection 7i71 according to best accounting practices4 #g4 ,,nih research information collection exempted from ,paperwork ,reduction ,act ,section #cja of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bda7 is amended by adding to the end the following3 7f7 ,paperwork reduction ,subchapter ,i of chapter #ce of title #dd1 ,united ,states ,code1 shall not apply to the collection of information during the conduct of research by the ,national ,institutes of ,health4 4 #h4 ,studies ,the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended-- 7#a7 in section #eje7k77#e7 7#ba ,u4,s4,c4 #cee7k77#e77-- 7,a7 in subparagraph 7,a71 by inserting and after the semicolon2 7,b7 by striking subparagraph 7,b72 and 7,c7 by redesignating subparagraph 7,c7 as subparagraph 7,b72 7#b7 in section #eje;,a 7#ba ,u4,s4,c4 #cee;a71 by striking subsection 7p72 7#c7 in section #eje;,b 7#ba ,u4,s4,c4 #cee;c7-- 7,a7 by striking subsection 7l72 and 7,b7 by redesignating subsection 7m7 as subsection 7l72 and 7#d7 in section #ebc 7#ba ,u4,s4,c4 #cfjm71 by striking subsection 7d74 #i4 ,summary level review ,section #eje7;c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;c77 is amended by adding at the end the following3 7#e7 7,a7 ,the ,secretary may rely upon qualified data summaries to support the approval of a supplemental application1 with respect to a qualified indication for a drug1 submitted under subsection 7b7 or section #cea7;a7 of the ,public ,health ,service ,act1 if such supplemental application complies with subparagraph 7,b74 7,b7 ,a supplemental application is eligible for review as described in subparagraph 7,a7 only if-- 7i7 there is existing data available and acceptable to the ,secretary demonstrating the safety of the drug2 and 7ii7 all data used to develop the qualified data summaries are submitted to the ,secretary as part of the supplemental application4 7,c7 ,in this paragraph-- 7i7 the term qualified indication means an indication for a drug that the ,secretary determines to be appropriate for summary level review under this paragraph2 and 7ii7 the term qualified data summary means a summary of clinical data that demonstrates the safety and effectiveness of a drug with respect to a qualified indication4 4 #aj4 ,drug surveillance 7a7 ,new drugs ,section #eje7k77#e7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7k77#e771 as amended by section #h1 is further amended-- 7#a7 in subparagraph 7,a71 by striking 1 bi-weekly screening and inserting screenings2 7#b7 in subparagraph 7,b71 as redesignated by section #h7a77;,c71 by striking the period at the end and inserting 2 and2 and 7#c7 by adding at the end the following3 7,c7 make available on the ,internet website of the ,food and ,drug ,administration-- 7i7 guidelines1 developed with input from experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs1 that detail best practices for drug safety surveillance using the ,,fda ,adverse ,event ,reporting ,systems2 and 7ii7 criteria for public posting of adverse event signals4 4 7b7 ,,faers revision ,section #eje7r77#b77;,d7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7r77#b77;,d77 is amended by striking 81 by #ah months0 and all that follows through the semicolon at the end of the subparagraph and inserting and making publicly available on the ,internet ,web site established under paragraph 7#a7 best practices for drug safety surveillance activities for drugs newly approved under this section or section #cea of the ,public ,health ,service ,act24 7c7 ,risk evaluation and mitigation strategies ,section #eje-a7;f77#e7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee-a7;f77#e77 is amended-- 7#a7 in the matter preceding subparagraph 7,a71 by inserting or other advisory committee after 7or successor committee72 and 7#b7 in subparagraph 7,b71 by striking at least annually1 and inserting periodically4 #aa4 ,biological product innovation ,section #cea7;j7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7;j77 is amended by striking except that and all that follows through the period at the end and inserting 8except that-- 7#a7 a product for which a license has been approved under this section shall not be required to have an approved application under section #eje of such ,act2 and 7#b7 those provisions of the ,federal ,food1 ,drug1 and ,cosmetic ,act that refer to an official compendium as defined under section #bja7;j7 of such ,act shall not apply to a biological product subject to regulation under this section4 4 #ab4 ,expanded access policy ,chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended by inserting after section #efa 7#ba ,u4,s4,c4 #cfj;bbb7 the following3 #efa;,a4 ,expanded access policy required for investigational drugs 7a7 ,in general ,the manufacturer or distributor of one or more investigational drugs for the diagnosis1 cure1 mitigation1 treatment1 or prevention of one or more serious diseases or conditions shall make available the policy of the manufacturer or distributor on evaluating and responding to requests submitted under section #efa7;b7 for provision of such a drug4 7b7 ,public availability of expanded access policy ,the policies under subsection 7a7 shall be made public and readily available1 such as by posting such policies on a publicly available ,internet website4 ,such policies may be generally applicable to all investigational drugs of such manufacturer or distributor4 7c7 ,content of policy ,a policy described in subsection 7a7 shall include-- 7#a7 contact information for the manufacturer or distributor to facilitate communication about requests described in subsection 7a72 7#b7 procedures for making such requests2 7#c7 the general criteria the manufacturer or distributor will use to evaluate such requests for individual patients1 and for responses to such requests2 and 7#d7 the length of time the manufacturer or distributor anticipates will be necessary to acknowledge receipt of such requests4 7d7 ,no guarantee of access ,the posting of policies by manufacturers and distributors under subsection 7a7 shall not serve as a guarantee of access to any specific investigational drug by any individual patient4 7e7 ,revised policy ,nothing in this section shall prevent a manufacturer or distributor from revising a policy required under this section at any time4 7f7 ,application ,this section shall apply to a manufacturer or distributor with respect to an investigational drug beginning on the later of-- 7#a7 the date that is #fj calendar days after the date of enactment of the ,,fda and ,,nih ,workforce ,authorities ,modernization ,act2 or 7#b7 the first initiation of a phase #b or phase #c study 7as such terms are defined in section #cab4ba7;b7 and 7c7 of title #ba1 ,code of ,federal ,regulations 7or any successor regulations77 with respect to such investigational drug4 4 #ac4 ,finalizing draft guidance on expanded access 7a7 ,in general ,not later than #a year after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services shall finalize the draft guidance entitled ,expanded ,access to ,investigational ,drugs for ,treatment ,use--,qs ,as1 dated ,may #bjac4 7b7 ,contents ,the final guidance described in subsection 7a7 shall explain how the ,secretary of ,health and ,human ,services considers and uses adverse drug event data reported by investigators in the case of data reported from use under a request submitted under section #efa7;b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb7b774 #ad4 ,amendments to the ,orphan ,drug ,act ,section #e of the ,orphan ,drug ,act 7#ba ,u4,s4,c4 #cfj;ee7 is amended-- 7#a7 in subsection 7a71 by striking paragraph 7#a7 and inserting the following3 7#a7 defraying the costs of developing drugs for rare diseases or conditions1 including qualified testing expenses1 2 and 7#b7 in subsection 7b77#a7-- 7,a7 in subparagraph 7,a77ii71 by striking 8and0 after the semicolon2 7,b7 in subparagraph 7,b71 by striking the period and inserting 82 and02 and 7,c7 by adding at the end the following3 7,c7 prospectively planned and designed observational studies and other analyses conducted to assist in the understanding of the natural history of a rare disease or condition and in the development of a therapy1 including studies and analyses to-- 7i7 develop or validate a drug development tool related to a rare disease or condition2 or 7ii7 understand the full spectrum of the disease manifestations1 including describing genotypic and phenotypic variability and identifying and defining distinct subpopulations affected by a rare disease or condition4 4 #ae4 ,standards for regenerative medicine and advanced therapies ,subchapter ,a of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cea et seq47 is amended by inserting after section #ejf;,f the following3 #ejf;,g4 ,standards for regenerative medicine and advanced therapies 7a7 ,in ,general ,the ,secretary1 in consultation with the ,national ,institute of ,standards and ,technology and stakeholders 7including regenerative medicine and advanced therapies manufacturers and clinical trial sponsors1 contract manufacturers1 academic institutions1 practicing clinicians1 regenerative medicine and advanced therapies industry organizations1 and standard setting organizations71 shall facilitate an effort to coordinate and prioritize the development of standards1 through a transparent public process1 that will help support product development1 evaluation1 and review1 with respect to regenerative medicine and advanced therapies1 through regulatory predictability1 including with regard to manufacturing processes and controls for regenerative medicine and advanced therapies products4 7b7 ,activities 7#a7 ,in ,general ,in carrying out this section1 the ,secretary shall continue to-- 7,a7 identify opportunities to help advance the development of regenerative medicine and advanced therapies2 7,b7 identify opportunities for the development of laboratory regulatory science research and documentary standards that the ,secretary determines would help support the development1 evaluation1 and review of regenerative medicine and advanced therapies through regulatory predictability2 and 7,c7 work with stakeholders1 such as those described in subsection 7a71 as appropriate1 in the development of such standards4 7#b7 ,regulations and guidance ,after the development of standards as described in subsection 7a71 the ,secretary shall review relevant regulations and guidance and1 through a transparent public process1 update such regulations and guidance as the ,secretary determines appropriate4 7c7 ,definition ,for purposes of this section1 the term #8regenerative medicine and advanced therapies' includes cell therapy1 gene therapy1 gene-modified cell therapy1 therapeutic tissue engineering products1 human cell and tissue products1 and combination products using any such therapies or products4 4 #af4 ,good guidance practices 7a7 ,in ,general ,section #gja7;h77#a77;,c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cga7;h77#a77;,c77 is amended-- 7#a7 by moving the margin of clause 7ii7 #b ems to the left2 and 7#b7 by adding at the end the following3 7iii7 ,when proposing or finalizing any guidance document under this subparagraph1 the ,secretary shall include in the guidance document a statement1 the contents of which are committed to the discretion of the ,secretary-- 7,i7 explaining why the interpretation or policy set forth in such guidance document is being provided in a nonbinding guidance document and not established through rulemaking2 and 7,,ii7 identifying each specific statutory provision or regulation being interpreted in the guidance document or authorizing a policy decision described in the guidance document4 4 7b7 ,effective date ,the amendment made under subsection 7a77#b7 shall take effect with respect to any applicable guidance documents that are issued on or after the date that is #c months after the date of enactment of this ,act4 #ag4 ,paperwork ,reduction ,act ,waiver ,during a ,public ,health ,emergency ,section #cai of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d7 is amended by adding at the end the following3 7f7 ,determination with respect to paperwork reduction act waiver during a public health emergency 7#a7 ,determination ,if the ,secretary determines1 after consultation with such public health officials as may be necessary1 that-- 7,a7 7i7 the criteria set forth for a public health emergency under paragraph 7#a7 or 7#b7 of subsection 7a7 has been met2 or 7ii7 a disease or disorder1 including a novel and emerging public health threat1 is significantly likely to become a public health emergency2 and 7,b7 the circumstances of such public health emergency1 or potential for such significantly likely public health emergency1 including the specific preparation for and response to such public health emergency or threat1 necessitate a waiver from the requirements of subchapter ,i of chapter #ce of title #dd1 ,united ,states ,code 7commonly referred to as the ,paperwork ,reduction ,act72 then the requirements of such subchapter ,i with respect to voluntary collection of information shall not be applicable during the immediate investigation of1 and response to1 such public health emergency during the period of such public health emergency or the period of time necessary to determine if a disease or disorder1 including a novel and emerging public health threat1 will become a public health emergency as provided for in this paragraph4 ,the requirements of such subchapter ,i with respect to voluntary collection of information shall not be applicable during the immediate post-response review regarding such public health emergency if such immediate post-response review does not exceed a reasonable length of time4 7#b7 ,transparency ,if the ,secretary determines that a waiver is necessary under paragraph 7#a71 the ,secretary shall promptly post on the ,internet website of the ,department of ,health and ,human ,services a brief justification for such waiver1 the anticipated period of time such waiver will be in effect1 and the agencies and offices within the ,department of ,health and ,human ,services to which such waiver shall apply1 and update such information posted on the ,internet website of the ,department of ,health and ,human ,services1 as applicable4 7#c7 ,effectiveness of waiver ,any waiver under this subsection shall take effect on the date on which the ,secretary posts information on the ,internet website as provided for in this subsection4 7#d7 ,termination of waiver ,upon determining that the circumstances necessitating a waiver under paragraph 7#a7 no longer exist1 the ,secretary shall promptly update the ,internet website of the ,department of ,health and ,human ,services to reflect the termination of such waiver4 7#e7 ,limitations 7,a7 ,period of waiver ,the period of a waiver under paragraph 7#a7 shall not exceed the period of time for the related public health emergency1 including a public health emergency declared pursuant to subsection 7a71 and any immediate post-response review regarding the public health emergency consistent with the requirements of this subsection4 7,b7 ,subsequent compliance ,an initiative subject to a waiver under paragraph 7#a7 that is ongoing after the date on which the waiver expires1 shall be subject to the requirements of subchapter ,i of chapter #ce of title #dd1 ,united ,states ,code1 and the ,secretary shall ensure that compliance with such requirements occurs in as timely a manner as possible based on the applicable circumstances1 but not to exceed #cj calendar days after the expiration of the applicable waiver4 4 #ah4 ,technical corrections 7a7 ,references ,except as otherwise expressly provided1 whenever in this subsection an amendment is expressed in terms of an amendment to a section or other provision1 the reference shall be considered to be made to that section or other provision of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et seq474 7b7 ,amendments 7#a7 ,prohibited ,acts ,section #cja7r7 of the ,act 7#ba ,u4,s4,c4 #cca7r77 is amended by inserting 1 drug1 after device each place the term appears4 7#b7 ,new ,drugs ,section #eje of the ,act 7#ba ,u4,s4,c4 #cee7 is amended-- 7,a7 in subsection 7d71 in the last sentence1 by striking premarket approval and inserting marketing approval2 and 7,b7 in subsection 7q77#e77;,a71 by striking subsection 7b77#b7 or 7j7 of the ,act or #cea7k7 and inserting subsection 7b77#b7 or 7j7 of this section or section #cea7k74 7#c7 ,risk evaluation and mitigation strategies ,section #eje-a7;h7 of the ,act 7#ba ,u4,s4,c4 #cee-a7;h77 is amended-- 7,a7 in paragraph 7#b77;,a77iii7-- 7i7 in the clause heading1 by striking label and inserting labeling2 7ii7 by striking label each place the term appears and inserting labeling2 and 7iii7 by striking sponsor and inserting responsible person2 and 7,b7 in paragraph 7#h71 by striking and 7#g74 and inserting and 7#g74 7#d7 ,pediatric study plans ,section #eje;,b of the ,act 7#ba ,u4,s4,c4 #cee;c7 is amended-- 7,a7 in subsection 7e7-- 7i7 in paragraph 7#b7-- 7,i7 in subparagraph 7,a71 in the matter preceding clause 7i71 by inserting study after initial pediatric each place the term appears2 and 7,,ii7 in subparagraph 7,b71 in the subparagraph heading1 by striking initial plan and inserting initial pediatric study plan2 7ii7 in paragraph 7#e71 by inserting agreed initial pediatric study before plan in the paragraph heading2 and 7iii7 in paragraph 7#f71 by striking agreed initial pediatric plan and inserting agreed initial pediatric study plan2 and 7,b7 in subsection 7f77#a71 by inserting and any significant amendments to such plans1 after agreed initial pediatric study plans14 7#e7 ,discontinuance or interruption in the production of live-saving drugs ,section #ejf;,c of the ,act 7#ba ,u4,s4,c4 #cef;c7 is amended-- 7,a7 in subsection 7c71 by striking discontinuation and inserting discontinuance2 and 7,b7 in subsection 7g77#a71 by striking section #eje7;j7 that could help and inserting section #eje7;j71 that could help4 7#f7 ,annual reporting on drug shortages ,section #ejf;,c-#a7;a7 of the ,act 7#ba ,u4,s4,c4 #cca7;a77 is amended1 in the matter before paragraph 7#a7-- 7,a7 by striking ,not later than the end of calendar year #bjac1 and not later than the end of each calendar year thereafter1 and inserting ,not later than ,march #ca of each calendar year1 2 and 7,b7 by inserting 1 with respect to the preceding calendar year1 after a report4 7#g7 ,drug shortage list ,section #ejf;,e7b77#c77;,e7 of the ,act 7#ba ,u4,s4,c4 #cef;e7b77#c77;,e77 is amended by striking discontinuation and inserting discontinuance4 7#h7 ,inspections of establishments ,section #eaj7;h7 of the ,act 7#ba ,u4,s4,c4 #cfj7;h77 is amended-- 7,a7 in paragraph 7#d71 in the matter preceding subparagraph 7,a71 by striking establishing the risk-based scheduled and inserting establishing a risk-based schedule2 and 7,b7 in paragraph 7#f7-- 7i7 in subparagraph 7,a71 by striking fiscal and inserting calendar each place the term appears2 and 7ii7 in subparagraph 7,b71 by striking an active ingredient of a drug1 a finished drug product1 or an excipient of a drug and inserting an active ingredient of a drug or a finished drug product4 7#i7 ,classification of devices intended for human use ,section #eac7;f77#b77;,a7 of the ,act 7#ba ,u4,s4,c4 #cfj;c7f77#b77;,a77 is amended-- 7,a7 in clause 7i71 by striking within #cj days2 and 7,b7 in clause 7iv71 by striking low-moderate and inserting low to moderate4 7#aj7 ,premarket approval ,section #eae7;a77#a7 of the ,act 7#ba ,u4,s4,c4 #cfj;e7a77#a77 is amended by striking subject to a an order and inserting subject to an order4 7#aa7 ,program to improve the device recall system ,section #eah;,a of the ,act 7#ba ,u4,s4,c4 #cfj;h-#a7 is amended-- 7,a7 by striking subsection 7c72 and 7,b7 by redesignating subsection 7d7 as subsection 7c74 7#ab7 ,unique device identifier ,section #eai7;f7 of the ,act 7#ba ,u4,s4,c4 #cfj;i7f77 is amended by striking and life sustaining and inserting or life sustaining4 7#ac7 ,priority review for qualified infectious disease products ,section #ebd;,a of the ,act 7#ba ,u4,s4,c4 #cfjn-#a7 is amended-- 7,a7 by striking ,if the ,secretary and inserting the following3 7a7 ,in ,general ,if the ,secretary 2 7,b7 by striking any and inserting the first2 and 7,c7 by adding at the end the following3 7b7 ,construction ,nothing in this section shall prohibit the ,secretary from giving priority review to a human drug application or efficacy supplement submitted for approval under section #eje7;b7 that otherwise meets the criteria for the ,secretary to grant priority review4 4 7#ad7 ,consultation with external experts on rare diseases1 targeted therapies1 and genetic targeting of treatments ,section #efi7;a77#b77;,a7 of the ,act 7#ba ,u4,s4,c4 #cfj;bbb-#h7;a77#b77;,a77 is amended1 in the first sentence1 by striking subsection 7c7 and inserting subsection 7b74 7#ae7 ,optimizing global clinical trials ,section #efi;,a7c7 of the ,act 7#ba ,u4,s4,c4 #cfj;bbb-#h;a7c77 is amended by inserting or under the ,public ,health ,service ,act after this ,act4 7#af7 ,use of clinical investigation data from outside the ,united ,states ,section #efi;,b of the ,act 7#ba ,u4,s4,c4 #cfj;bbb-#h;b7 is amended by striking drug or device and inserting drug1 biological product1 or device each place the term appears4 7#ag7 ,medical gases definitions ,section #ege7a77;,h7 of the ,act 7#ba ,u4,s4,c4 #cfj;ddd7#a77;,h77 is amended-- 7,a7 by inserting for a new drug after any period of exclusivity2 and 7,b7 by inserting or any period of exclusivity for a new animal drug under section #eab7;c77#b77;,f71 after section #eje;,a14 7#ah7 ,regulation of medical gases ,section #egf7;a7 of the ,act 7#ba ,u4,s4,c4 #cfj;ddd-#a7;a77 is amended-- 7,a7 in the matter preceding subparagraph 7,a7 of paragraph 7#a71 by inserting who seeks to initially introduce or deliver for introduction a designated medical gas into interstate commerce after any person2 and 7,b7 in paragraph 7#c7-- 7i7 in subparagraph 7,a7-- 7,i7 in clause 7i77,,viii71 by inserting for a new drug after any period of exclusivity2 and 7,,ii7 in clause 7ii71 in the matter preceding subclause 7,i71 by inserting the before final use2 and 7ii7 in subparagraph 7,b7-- 7,i7 in clause 7i71 by inserting for a new drug after any period of exclusivity2 and 7,,ii7 in clause 7ii71 by inserting a comma after drug product4 7#ai7 ,inapplicability of drug fees to designated medical gases ,section #egg of this ,act 7#ba ,u4,s4,c4 #cfj;ddd-#b7 is amended by inserting or #gdj7;a7 after section #gcf7;a74 7#bj7 ,conflicts of interest ,section #gab7;e77#a77;,b7 of the ,act 7#ba ,u4,s4,c4 #cgi;d-#a7;e77#a77;,b77 is amended by striking services and inserting service4 7#ba7 ,authority to assess and use biosimilar biological product fees ,section #gdd;,h7a7 of the ,act 7#ba ,u4,s4,c4 #cgi;j-#eb7;a77 is amended-- 7,a7 in paragraph 7#a77;,a77v71 by striking ,biosimilars ,user ,fee ,act of #bjab and inserting ,biosimilar ,user ,fee ,act of #bjab2 and 7,b7 in paragraph 7#b77;,b71 by striking ,biosimilars ,user ,fee ,act of #bjab and inserting ,biosimilar ,user ,fee ,act of #bjab4 7#bb7 ,registration of commercial importers 7,a7 ,amendment ,section #hja7s77#b7 of the ,act 7#ba ,u4,s4,c4 #cha7s77#b77 is amended by adding at the end the following3 7,d7 ,effective date ,in establishing the effective date of the regulations under subparagraph 7,a71 the ,secretary shall1 in consultation with the ,secretary of ,homeland ,security acting through ,u4,s4 ,customs and ,border ,protection1 as determined appropriate by the ,secretary of ,health and ,human ,services1 provide a reasonable period of time for an importer of a drug to comply with good importer practices1 taking into account differences among importers and types of imports1 including based on the level of risk posed by the imported product4 4 7,b7 ,conforming amendment ,section #gad of the ,food and ,drug ,administration ,safety and ,innovation ,act 7,public ,law #aab-add2 #abf ,stat4 #ajgd7 is amended by striking subsection 7d74 7#bc7 ,recognition of foreign government inspections ,section #hji7;a77#b7 of the ,act 7#ba ,u4,s4,c4 #chd;e7a77#b77 is amended by striking conduction and inserting conducting4 7#bd7 ,findings relating to drug approval ,section #ija7;a77#a77;,a7 of the ,food and ,drug ,administration ,safety and ,innovation ,act 7,public ,law #aab-add2 #ba ,u4,s4,c4 #cef note7 is amended by striking serious and life-threatening diseases and inserting serious or life-threatening diseases4 7#be7 ,reporting of inclusion of demographic subgroups ,section #ijg of the ,food and ,drug ,administration ,safety and ,innovation ,act 7,public ,law #aab-add2 #abf ,stat4 #ajib1 #ajic7 is amended-- 7,a7 in the section heading1 by striking ,biologics in the heading and inserting ,biological ,products2 and 7,b7 in subsection 7a77#b77;,b71 by striking applications for new drug applications and inserting new drug applications4 7#bf7 ,combating prescription drug abuse ,section #aabb of the ,food and ,drug ,administration ,safety and ,innovation ,act 7,public ,law #aab-add2 #abf ,stat4 #aaab1 #aaac7 is amended-- 7,a7 in subsection 7a77#b71 by striking dependance and inserting dependence2 and 7,b7 in subsection 7c71 by striking promulgate and inserting issue4 ,april #ah1 #bjaf,reported with an amendment